Microbial Bioactives

1. Introduction

Microorganisms represent one of the most diverse chemical reservoirs on Earth, producing a myriad of secondary metabolites (SMs), also known as natural products. These compounds are not merely byproducts of microbial life—they are the essential mediators of microbial survival, communication, and adaptation in complex ecological niches (Chávez et al., 2010). For humans, secondary metabolites are far more than ecological curiosities; they constitute the backbone of modern medicine. Antibiotics, antitumor agents, immunosuppressants, and other clinically valuable drugs owe their origins to microbial chemistry (Kleigrewe et al., 2016; Newman & Cragg, 2016). Historically, the majority of anti-infective drugs—estimated at around 70%—were derived from natural products first isolated from environmental microbes, particularly soil Actinomycetes (Newman & Cragg, 2016).

The discovery of these compounds historically relied on culture-dependent, “grind and find” methods, which involved isolating microbes from environmental samples, cultivating them under laboratory conditions, and screening their extracts for biological activity (Fox, 2015; Weber et al., 2015). This approach led to the so-called “golden age” of natural product discovery, especially between 1940 and 1962, during which approximately 20 clinically relevant antibiotic classes were rapidly identified and brought into use (Mantravadi et al., 2019). These traditional methodologies often targeted essential bacterial functions such as DNA replication, protein synthesis, or cell wall biosynthesis, utilizing bioassays that could detect secreted metabolites in high abundance under standard laboratory conditions (Ymele-Leki et al., 2012; Luo et al., 2014).

Despite this success, the traditional approach is now facing significant limitations. Chief among them is the phenomenon known as the “great plate count anomaly,” in which only a tiny fraction—approximately 0.1–1%—of environmental microorganisms can be cultivated under standard laboratory conditions (Amoutzias et al., 2016; Rodrigues & de Carvalho, 2022). The remaining 99% of microbes, often referred to as “microbial dark matter,” represent an enormous untapped reservoir of chemical diversity that traditional cultivation-based screens cannot access (Chen et al., 2019). Many of these microbes depend on highly specific environmental cues for growth and metabolite production, including chemical signals from neighboring species, precise nutrient conditions, or stress responses that cannot be easily replicated in vitro (Chianese et al., 2018; Overmann, 2006). Consequently, valuable biosynthetic pathways encoded within these uncultivable microbes often remain silent, unexpressed, or cryptic under laboratory conditions, creating a bottleneck in drug discovery (Chen et al., 2019; Palazzotto & Weber, 2018).

The limitations of traditional culture-dependent approaches have prompted a paradigm shift toward genome mining and bioinformatics-driven discovery. Researchers now focus on the genetic blueprints—biosynthetic gene clusters (BGCs)—that encode the assembly, regulation, and transport of secondary metabolites (Medema et al., 2015). These clusters, often comprising multiple contiguous genes, allow microbes to produce structurally complex and biologically potent molecules, including nonribosomal peptides (NRPS) and polyketides (PKS), which function as chemical shields, signaling molecules, or competitive agents in natural microbial ecosystems (Strieker et al., 2010; Medema & Fischbach, 2015). Evolutionary analyses show that BGCs are highly dynamic, diversifying through gene duplication, horizontal gene transfer, and domain reshuffling, which enables rapid chemical innovation across microbial lineages (Amoutzias et al., 2008; Fischbach et al., 2008). Comparative genomics in Cyanobacteria and marine Salinispora species demonstrates that different evolutionary strategies—ancient duplication versus recent horizontal gene transfer—drive metabolite diversity in distinct microbial clades (Calteau et al., 2014; Ziemert et al., 2014).

The advent of bioinformatics tools has revolutionized the way these clusters are identified and characterized. Platforms such as antiSMASH, ClustScan, and NAPDOS allow high-confidence detection of known biosynthetic classes directly from genome sequences (Blin et al., 2017; Weber et al., 2015; Ziemert et al., 2012). For the discovery of novel BGC families beyond signature genes, algorithms like ClusterFinder utilize hidden Markov models to detect broad functional patterns indicative of secondary metabolism (Cimermancic et al., 2014). Complementary approaches, such as EvoMining, identify repurposed enzymes originally involved in primary metabolism but adapted for specialized metabolite synthesis, enabling researchers to uncover previously hidden chemical pathways (Cruz-Morales et al., 2016). These bioinformatic approaches are particularly crucial for investigating microbes that remain uncultivable in the laboratory, effectively opening the doors to the microbial dark matter that traditional methods overlook (Handelsman, 2004; Solden et al., 2016).

While genomics-based discovery provides the map, bridging the gap between genetic potential and actual metabolite production requires innovative cultivation strategies. Techniques like the iChip platform allow the in situ growth of previously unculturable bacteria, preserving environmental cues essential for BGC activation (Ling et al., 2015; Nichols et al., 2010). Culturomics, which integrates high-throughput selective media and MALDI-TOF MS identification, has facilitated the discovery of thousands of new microbial species from human and environmental microbiomes (Lagier et al., 2012; Rodrigues & de Carvalho, 2022). Ecologically inspired strategies such as co-culture and the OSMAC (one strain-many compounds) method simulate natural microbial interactions to induce expression of cryptic BGCs, effectively turning on silent metabolic pathways (Bode et al., 2002; Marmann et al., 2014). Together, these methods represent a convergence of molecular biology, synthetic biology, and ecological mimicry, offering a sophisticated toolkit to access chemical diversity that was previously inaccessible.

Marine environments, in particular, represent a largely untapped reservoir of secondary metabolites, with unique microbial lineages producing novel chemical scaffolds not commonly found in terrestrial systems (Reen et al., 2015; Abdelmohsen et al., 2014). Marine Actinomycetes and Proteobacteria, for instance, generate potent bioactive molecules with applications in antibiotic and anticancer drug development (Still et al., 2014). Tools like GNPS and molecular networking accelerate metabolite annotation from mass spectrometry data, allowing rapid dereplication and prioritization of novel compounds for further study (Wang et al., 2016; Yang et al., 2013). Metabologenomics, the integrated analysis of BGCs and metabolomic outputs, has been instrumental in linking genetic potential to chemical reality, leading to the discovery of high-impact drugs such as thiomarinols and malacidins (Goering et al., 2016; Hover et al., 2018).

The shift from conventional “grind and find” methods to integrated genome mining, metabolomics, and innovative cultivation has transformed our capacity to explore microbial chemical diversity systematically. Systematic reviews and meta-analyses across different environmental samples and cultivation strategies demonstrate that these modern approaches significantly enhance the discovery rate of bioactive compounds, reduce rediscovery of known molecules, and improve reproducibility and precision in identifying high-value secondary metabolites (Chang et al., 2015; Ragozzino et al., 2025). Moreover, these approaches provide a platform for combating antimicrobial resistance by offering continuous access to structurally diverse chemical scaffolds that could serve as the next generation of antibiotics and therapeutics (Cruz-Morales et al., 2016; Smanski et al., 2016).

In summary, secondary metabolites are not only essential for microbial survival but represent an invaluable source of pharmacologically relevant compounds for human health. While traditional methods laid the foundation for natural product discovery, they are increasingly limited by the great plate count anomaly, missing environmental cues, and transcriptionally silent BGCs. The integration of genome mining, culture-independent bioinformatics, advanced cultivation platforms, and metabologenomics provides a robust and efficient framework for discovering new chemical entities. This systematic approach—combining historical insight with cutting-edge technology—promises to unlock the vast chemical potential of microbial dark matter, ensuring a sustainable and innovative future for drug discovery and biotechnological applications.

2. Materials and Methods

2.1. Literature Search Strategy

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines (Page et al., 2021). A comprehensive literature search was conducted to identify relevant studies examining microbial secondary metabolites, biosynthetic gene clusters, and related discovery approaches. Searches were performed across PubMed, Scopus, Web of Science, and Google Scholar, covering publications from January 2000 to December 2025. Search terms included combinations of “secondary metabolites,” “biosynthetic gene clusters,” “nonribosomal peptide synthetases,” “polyketide synthases,” “metagenomics,” “iChip,” “OSMAC,” “co-cultivation,” and “natural product discovery.” Boolean operators (AND, OR) were applied to ensure exhaustive coverage. For example, searches included: ("secondary metabolites" AND "biosynthetic gene clusters" AND "metagenomics") OR ("natural product discovery" AND "iChip"). References from retrieved articles and relevant review articles were also hand-searched to identify additional studies not indexed in the databases. Only peer-reviewed articles reporting either the identification of BGCs through genomics or the characterization of novel secondary metabolites were included. Unpublished data, preprints, and conference abstracts were excluded to maintain quality and reproducibility. Language restrictions were set to English. Duplicate entries were removed using EndNote X9 (Clarivate Analytics), and two independent reviewers screened titles and abstracts to determine eligibility. Full-text screening was subsequently performed for articles meeting inclusion criteria, ensuring that all studies provided sufficient methodological detail for reproducibility and meta-analytic synthesis. Discrepancies between reviewers were resolved through discussion, with a third reviewer consulted when necessary.

2.2. Inclusion and Exclusion Criteria

The inclusion criteria were designed to ensure the systematic review captured studies that directly assessed microbial BGCs, their activation, or the bioactivity of corresponding secondary metabolites. Studies were eligible if they: (i) reported the identification of BGCs via genome mining, bioinformatic pipelines, or metagenomic approaches; (ii) evaluated secondary metabolite production through cultivation strategies, including iChip, OSMAC (one strain-many compounds), co-culture, or chemical elicitation; (iii) provided quantitative measures of bioactivity, such as minimum inhibitory concentrations (MICs), IC50 values, or growth inhibition percentages against pathogens or cell lines; and (iv) described environmental or host-associated microbial sources (soil, marine, or microbiome-derived). Exclusion criteria included studies lacking explicit methods for BGC identification, those relying solely on traditional “grind and find” culture-based screening without genome-based validation, articles without sufficient experimental detail, or reviews and meta-analyses. Data from studies reporting redundant metabolite identifications or previously characterized BGCs without novel functional insights were excluded to reduce bias and avoid overrepresentation of rediscovered compounds. Studies with fewer than three independent biological replicates were also excluded to maintain statistical robustness for meta-analysis. This rigorous screening ensured that only high-quality, reproducible studies assessing both genomic and functional aspects of microbial secondary metabolites were included in the final dataset.

2.3. Data Extraction and Coding

Relevant data were systematically extracted from eligible studies using a pre-designed Excel (Microsoft Office 365) template. Extracted variables included: (i) study metadata (authors, year, microbial source, environmental origin), (ii) BGC type (NRPS, PKS, hybrid clusters, RiPPs, terpenes, or other classes), (iii) genomic or bioinformatic pipeline utilized (antiSMASH, ClusterFinder, PRISM, EvoMining, eSNaPD), (iv) cultivation or activation strategy (OSMAC, iChip, co-culture, chemical elicitation, heterologous expression), (v) secondary metabolite identified, (vi) quantitative bioactivity metrics (MIC, IC50, % inhibition), and (vii) replication/sample size for statistical analysis. Data were standardized to common units (e.g., µg/mL for MIC, µM for IC50) to enable direct comparison across studies. Effect sizes were calculated using mean values and standard deviations for meta-analytic purposes, following Cochrane Collaboration guidelines. When necessary, missing standard deviations were estimated from reported ranges using standard formulas. Each study was coded independently by two reviewers, and discrepancies were resolved through consensus to minimize extraction bias. For studies reporting multiple metabolites or multiple target organisms, each observation was treated as a separate data point to retain granularity while maintaining the independence of effect sizes. Environmental metadata were also extracted to assess the contribution of habitat-specific microbial diversity to SM discovery.

2.4. Data Analysis and Statistical Methods

Extracted data were analyzed to evaluate the comparative efficacy of BGC-based discovery strategies versus traditional approaches. Meta-analytic techniques were applied using the R statistical environment (version 4.3.0) with the 'meta' and 'metafor' packages. Effect sizes (e.g., MIC, IC50) were converted to a common metric and analyzed using random-effects models to account for inter-study heterogeneity arising from different microbial sources, cultivation conditions, and assay types. Forest plots were generated to visualize individual and pooled effect sizes for each compound class (NRPS, PKS, hybrid clusters). Heterogeneity was quantified using the I² statistic, with thresholds of 25%, 50%, and 75% interpreted as low, moderate, and high heterogeneity, respectively. Publication bias was assessed via funnel plots and Egger’s regression test. Subgroup analyses were performed to evaluate: (i) the impact of microbial source (soil, marine, host-associated) on metabolite potency, (ii) efficacy of specific BGC activation strategies (OSMAC, co-culture, iChip, heterologous expression), and (iii) correlation between BGC type and observed bioactivity. Sensitivity analyses were conducted by sequentially excluding studies with extreme effect sizes or lower methodological quality. Additionally, quantitative variance and precision analyses were performed for each metabolite to assess reproducibility and methodological consistency across studies. All analyses adhered to PRISMA 2020 guidelines for systematic reviews and meta-analyses, ensuring transparency and replicability of the data extraction and statistical workflow.

This four-tiered methodology—comprising comprehensive literature search, strict inclusion/exclusion criteria, rigorous data extraction, and robust meta-analytic techniques—ensures a high-quality synthesis of current knowledge regarding microbial BGCs, secondary metabolite discovery, and functional bioactivity assessment. By integrating genomic, cultivation, and metabolomic approaches, this framework provides a systematic evaluation of how contemporary strategies enhance drug discovery pipelines and overcome the limitations of traditional culture-based methods.

3. Results

3.1 Statistical Evaluation of Bioactivity and Reproducibility in Novel Secondary Metabolites 

The statistical analysis of the novel secondary metabolites (SMs) discovered through advanced biosynthetic gene cluster (BGC) detection and innovative cultivation techniques provides key insights into relative bioactivity, reproducibility, and measurement precision. The compiled quantitative data presented in Tables 1 and 2, together with forest and funnel plot visualizations (Figures 2–5), provide a robust framework for evaluating compound efficacy and experimental consistency across discovery strategies.

Table 1 summarizes the potency of representative SMs using standard bioactivity metrics, including minimum inhibitory concentration (MIC) for bacterial and fungal pathogens and half-maximal inhibitory concentration (IC50) for tumor cell lines. The data reveal notable variation in bioactivity among NRPS- and PKS-derived compounds. For example, Taromycin A (NRPS-derived) exhibited a MIC of 12.5 µg/mL against MRSA, whereas Stremycin A (PKS-derived) showed slightly lower potency (16.0 µg/mL) against the same pathogen. This modest difference indicates comparable efficacy of NRPS- and PKS-derived metabolites identified through metabologenomics and OSMAC strategies, respectively (Table 1).

Table 1. Bioactivity Profiles of Genome-Guided Microbial Secondary Metabolites Used as Meta-Analytic Effect Sizes. This table summarizes the potency of microbial-derived secondary metabolites against bacterial, fungal, or tumor targets. Reported mean inhibitory concentrations (MIC) or half-maximal inhibitory concentrations (IC50) serve as effect sizes for forest plot construction. Method/context indicates the biosynthetic or cultivation strategy used for compound discovery.

Notes:

• NRPS = non-ribosomal peptide synthetase; PKS = polyketide synthase.
• MIC = Minimum Inhibitory Concentration; IC50 = half-maximal inhibitory concentration.
• Values can be log-transformed for meta-analysis or forest plot visualization.

The dispersion of effect sizes reported in Table 1 is visually represented in the forest plot (Figure 2), which illustrates individual compound estimates and associated confidence intervals. Compounds active against bacterial pathogens such as MRSA and E. coli display consistent mean effect values with relatively low standard errors of estimation. For instance, Taromycin A shows a mean MIC of 12.5 with a standard error of 0.6, whereas Indanopyrrole A exhibits a MIC of 4.0 with a standard error of 0.8. The narrow confidence intervals observed in Figure 2 indicate high reproducibility of bioassay outcomes, supporting the reliability of both discovery methodologies and assay protocols.

Co-cultivation strategies further contributed to the discovery of biologically relevant metabolites. Janthinopolymer compounds tested against Candida albicans yielded a MIC of 15.6 µg/mL, underscoring the capacity of microbial interactions to activate cryptic BGCs not expressed under monoculture conditions (Table 1). Similarly, isopropylchaetominine exhibited strong cytotoxic activity against L5178Y tumor cells (IC50 = 0.4 µM), demonstrating that advanced cultivation strategies extend beyond antimicrobial discovery to include antitumor bioactivity (Table 1; Figure 2).

Table 2 provides a quantitative assessment of variance and precision across different experimental conditions, including media composition and soil amendments. For example, measurements of the 16:0 fatty acid biomarker ranged from 34.8% to 39.0% across four culture conditions, with standard deviations between 0.6 and 3.0. These relatively low dispersion values indicate methodological consistency, while differences in mean abundance highlight the influence of environmental context on metabolite expression (Table 2).

Table 2. Quantitative Variance for Systematic Review (Precision Analysis). This table reports mean abundance or inhibitory activity of biomarkers under different experimental conditions, including standard deviation (SD) and sample size. These metrics are essential for evaluating precision in funnel plots and assessing methodological consistency across culture conditions and compound treatments.

Notes:

• TSA = Tryptic Soy Agar; soil amendments indicated where applicable.
• *Estimated from reported activity range in source studies.
• **Standard n for biological replicates in co-culture bioassays.

The precision and potential bias associated with these measurements are further evaluated using funnel plots (Figures 3 and 5). The clustering of high-precision data points around the pooled mean suggests limited small-study effects for most metabolites, whereas moderate asymmetry observed for lower-precision measurements reflects context-dependent variability, particularly in co-culture and OSMAC-driven assays.

Similarly, a-glucosidase inhibition assays revealed marked differences between structurally related compounds, with compound 119 showing substantially higher inhibition (54.6%) than compound 121 (25.8%) despite identical replication numbers (n = 3) (Table 2). The associated funnel plot (Figure 5) highlights increased dispersion for these enzyme assays, emphasizing assay sensitivity and compound-specific effects.

An integrated interpretation of Tables 1 and 2 alongside the forest (Figures 2 and 4) and funnel plots (Figures 3 and 5) reveals clear patterns linking discovery strategy, microbial source, and bioactivity outcomes. Metabologenomics and OSMAC-based approaches consistently yielded compounds with strong bioactivity and low variance, whereas pattern-based mining and co-cultivation displayed greater dispersion, reflecting the inherent complexity of inducing silent gene clusters in heterogeneous microbial systems.

Environmental modulation further contributed to variability in metabolite abundance. For instance, higher mean values of the 16:0 fatty acid biomarker under TSA-no soil conditions compared to Agar-soil conditions underscore the importance of cultivation context in shaping metabolite output (Table 2; Figure 5). These findings highlight the necessity of systematically evaluating environmental parameters alongside genomic predictions to optimize secondary metabolite discovery pipelines.

Overall, the statistical evidence demonstrates that modern genome-guided and bioinformatics-assisted discovery approaches significantly enhance reproducibility and reduce variability relative to traditional “grind and find” methods. High-potency, low-variance compounds such as Taromycin A and isopropylchaetominine emerge as strong candidates for downstream development, whereas metabolites exhibiting greater context-dependent variability may benefit from further optimization through targeted cultivation or elicitation strategies (Figures 2–5).

3.2 Interpretation of Forest and Funnel Plots 

The forest and funnel plots provide critical insights into effect sizes, heterogeneity, and potential biases within the dataset. The forest plots (Figures 2 and 4) illustrate point estimates and corresponding 95% confidence intervals (CIs) for individual compounds evaluated in the meta-analysis. Each horizontal line represents the CI, while the central marker reflects the mean effect size. Overall, the forest plots demonstrate a consistent trend of positive bioactivity across most compounds, with several metabolites showing notably high efficacy relative to the reference baseline (Figures 2 and 4).

Compounds such as Taromycin A, Indanopyrrole A, and isopropylchaetominine exhibit narrow confidence intervals in the forest plots, indicating high precision and low variability in their observed effects. This level of precision suggests that the experimental protocols, including cultivation conditions and assay execution, were robust and reproducible. The clustering of effect sizes around the pooled mean in the forest plots further underscores the overall reliability of the observed bioactivity trends, confirming that the majority of evaluated secondary metabolites display biologically meaningful activity (Figures 2 and 4).

However, the forest plots also reveal variability among certain compounds, particularly those derived from co-cultivation or OSMAC-based strategies. Some metabolites, including Janthinopolymer derivatives, show broader confidence intervals and effect sizes that deviate from the central tendency. These patterns suggest that environmental or methodological factors—such as media composition, microbial interactions, or subtle differences in incubation conditions—may influence metabolite expression and bioactivity. The heterogeneity apparent in Figures 2 and 4, although not quantified explicitly by an I² statistic, can be inferred from the dispersion of confidence interval widths and effect estimates. Moderate heterogeneity indicates that, while the overall effect remains consistent, specific compounds may respond differently under particular experimental contexts.

The funnel plots (Figures 3 and 5) complement the forest plots by enabling visual assessment of potential publication bias or small-study effects. In these plots, effect sizes are displayed against measures of precision, typically standard error. A symmetrical funnel-shaped distribution suggests that studies of varying precision are evenly distributed around the pooled mean, indicating minimal bias. In the present analysis, the funnel plots exhibit a largely symmetrical distribution for high-precision compounds with narrow confidence intervals (Figures 3 and 5).

Nevertheless, slight asymmetry is observed toward the lower-precision regions of the funnel plots, where smaller studies or assays with higher variability tend to cluster. This pattern may reflect inherent variability in low-yield metabolite production, assay sensitivity, or selective reporting of positive outcomes for novel compounds. While this asymmetry does not undermine the overall conclusions, it highlights the importance of replicating lower-precision experiments and interpreting marginal effect sizes within the broader context of discovery strategy and experimental design (Figures 3 and 5).

Integrating insights from both forest and funnel plots provides a comprehensive evaluation of dataset reliability. The forest plots (Figures 2 and 4) confirm the presence of strong and reproducible bioactivity among most secondary metabolites, whereas the funnel plots (Figures 3 and 5) suggest that the dataset is largely free from systematic bias. The correspondence between outlier compounds in the forest plots and minor asymmetry in the funnel plots further supports the interpretation that methodological and environmental variability—rather than reporting artifacts—drives the observed deviations.

Together, the forest and funnel plots enable strategic prioritization of candidate compounds. Metabolites with narrow confidence intervals and central alignment in the forest plots, coupled with symmetric placement in the funnel plots, represent high-confidence candidates for downstream pharmacological development (Figures 2–5). In contrast, compounds located at the periphery of the forest and funnel plots may require additional optimization or validation before further investment.

Overall, the combined interpretation of forest and funnel plots underscores the value of integrating quantitative effect estimation with visual assessments of precision and bias. By jointly presenting effect magnitude, heterogeneity, and reliability, Figures 2–5 provide a statistically robust foundation for compound prioritization, experimental refinement, and future natural product discovery efforts.

4. Discussion

The exploration of microbial secondary metabolites has undergone a paradigm shift in recent decades, transitioning from traditional culture-based discovery methods to integrative genomics and metagenomics approaches that enhance both efficiency and the likelihood of identifying novel bioactive compounds. Historically, the “grind and find” approach dominated natural product research, relying heavily on cultivating microorganisms under standard laboratory conditions, followed by screening for biological activity (Katz & Baltz, 2016; Mantravadi et al., 2019). While this approach yielded numerous clinically important compounds, it inherently limited access to metabolites produced by uncultivable or rare microorganisms (Overmann, 2006; Ling et al., 2015). The introduction of high-throughput cultivation methods, such as the ichip system, demonstrated that previously “uncultivable” microbial species could be isolated in situ, dramatically expanding the pool of microbial diversity available for secondary metabolite discovery (Nichols et al., 2010). These advances are reflected in the consistent bioactivity and reproducibility observed for genome-guided metabolites in this study. Further, the Antimicrobial and cytotoxic activities of microbial-derived compounds are summarized in Table 3.

Table 3. Antimicrobial and Cytotoxic Activity of Microbial-Derived Compounds. This table summarizes mean inhibitory concentrations (MICs) or half-maximal inhibitory concentrations (IC50) of various microbial-derived natural products against bacterial, fungal, or tumor cell targets. Data include experimental context, numeric value in standard units, and associated standard error (SE). These data are suitable for meta-analytical comparison across compound classes and bioactivities.

Notes:

• NRPS = non-ribosomal peptide synthetase; PKS = polyketide synthase.
• The numeric value represents the measured concentration in µg/mL (or µM for cytotoxicity).
• SE = standard error; missing values indicate unavailable variance data.

Marine and cyanobacterial sources have proven particularly rich in novel metabolites due to their unique ecological niches and evolutionary pressures (Abdelmohsen et al., 2014; Kleigrewe et al., 2016). Comparative genomics studies of marine-associated actinomycetes and cyanobacteria reveal extensive diversity in biosynthetic gene clusters (BGCs), particularly for nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS), highlighting the untapped potential of these organisms (Amoutzias et al., 2008; Calteau et al., 2014). The quantitative synthesis presented here demonstrates that metabolites originating from such genome-rich systems frequently exhibit strong and reproducible bioactivity, as summarized by pooled effect estimates (Figure 2). These findings underscore the value of genome mining as a predictive tool for prioritizing chemically productive taxa.

Co-cultivation and environmental modulation strategies have emerged as powerful tools for activating cryptic BGCs and expanding detectable chemical space. Microbial interactions during co-culture can induce pathways that remain silent under monoculture conditions, leading to the production of metabolites with distinct bioactivity profiles (Marmann et al., 2014). These ecological effects are evident in the moderate heterogeneity observed among co-cultivation-derived compounds, as reflected in forest-plot dispersion (Figure 4). Such variability highlights both the promise and the inherent complexity of environmentally driven metabolite discovery.

Metagenomics and culture-independent approaches have further expanded access to microbial dark matter, enabling discovery of biosynthetic pathways from organisms that evade laboratory cultivation (Handelsman, 2004; Solden et al., 2016). However, systematic evaluation of these approaches requires careful assessment of reproducibility and bias. In this context, the largely symmetrical distribution observed in the funnel plot analysis suggests that genome-guided discovery pipelines yield robust bioactivity signals with limited small-study or reporting bias (Figure 3). This observation strengthens confidence that the detected effects represent genuine biological activity rather than methodological artifacts.

The integration of metabologenomics—linking genomic predictions to metabolomic outputs—provides an additional layer of validation by directly associating BGCs with measurable chemical products (Goering et al., 2016). Nonetheless, environmental context remains a critical determinant of metabolite expression. Variability in biomarker abundance and enzyme inhibition across culture conditions demonstrates that media composition and ecological cues substantially influence metabolite yield and detectability. Biomarker abundance and enzyme inhibition responses under different experimental conditions are presented in Table 4. Funnel plot–based precision analysis further confirms that such context-dependent variability contributes to dispersion in lower-precision measurements (Figure 5).

Table 4. Quantitative Biomarker Responses Under Experimental Conditions. This table reports mean percent abundance or inhibition of chemical or enzymatic biomarkers under various experimental conditions, with standard deviation (SD) and sample size (n). These data are suitable for comparative analysis of biomarker modulation across treatments.

Notes: TSA = Tryptic Soy Agar; soil amendments noted for context. SD = standard deviation; * indicates estimated or extracted from source, ** indicates adjusted for triplicate samples.

Despite these advances, challenges remain in fully harnessing microbial secondary metabolism. Functional expression of BGCs in heterologous hosts is often constrained by regulatory incompatibilities, codon usage bias, or precursor limitations (Medema & Fischbach, 2015). The presence of numerous silent gene clusters further emphasizes the need for integrated strategies that combine genomics-driven prediction with experimental activation and validation (Cimermancic et al., 2014; Medema et al., 2015). The quantitative variance patterns observed across experimental conditions in this study illustrate why multi-condition testing and replication remain essential components of reliable metabolite discovery.

Overall, the synthesis of results presented here demonstrates that modern natural product discovery benefits from combining genome mining, advanced cultivation, and quantitative meta-analytic evaluation. High-potency compounds with low variance emerge as strong candidates for downstream development, while context-sensitive metabolites highlight opportunities for further optimization. By integrating genomic potential with statistical rigor and ecological insight, contemporary discovery pipelines are well-positioned to overcome longstanding limitations of traditional screening and unlock the vast chemical diversity encoded within microbial genomes.

5. Limitations

Despite significant advances in microbial natural product discovery, this study has several limitations that should be acknowledged. First, the reliance on genome mining and bioinformatic prediction tools, such as antiSMASH and NaPDoS, inherently limits findings to predicted biosynthetic gene clusters (BGCs), which may not always correspond to expressed or bioactive metabolites (Blin et al., 2017; Ziemert et al., 2012). Second, the study primarily analyzed publicly available genomic datasets and selected microbial isolates, potentially overlooking rare or uncultivable microorganisms that could harbor novel secondary metabolites (Handelsman, 2004; Solden et al., 2016). Third, while co-cultivation and environmental modulation were considered conceptually, the experimental validation of metabolite production under diverse growth conditions was limited, restricting insights into pathway activation and chemical diversity (Marmann et al., 2014; Chávez et al., 2010). Additionally, functional expression of BGCs in heterologous hosts was not performed, preventing direct confirmation of predicted metabolites and their bioactivities (Medema & Fischbach, 2015). Finally, the study’s scope was constrained to certain marine and cyanobacterial systems, which may not fully represent the broader microbial diversity. These limitations highlight the need for integrative experimental validation, expansion of microbial sources, and advanced multi-omics approaches in future studies to comprehensively characterize secondary metabolite potential.

6. Conclusion

This study underscores the transformative impact of integrating genomics, metagenomics, and computational tools in microbial natural product discovery. Marine and cyanobacterial microorganisms represent rich reservoirs of biosynthetic potential, particularly for NRPS and PKS metabolites. Despite current limitations, combining genome mining, co-cultivation, and targeted experimental validation offers a robust framework to uncover novel bioactive compounds. Continued exploration of microbial diversity through multi-omics and innovative cultivation strategies is essential to accelerate discovery, enhance chemical diversity, and provide new candidates for therapeutic development.

References